Busetto concludes: "In this analysis of individuals with obesity aged 65 years and older, semaglutide reduced body weight and improved cardiometabolic risk factors compared with placebo, and the safety and efficacy profile of semaglutide was consistent with that reported in the STEP program." He adds: "In many countries, including many high-income countries, the majority of the cases of excess weight actually occur in adults aged 65 years and over, representing a major driver for obesity-related complications and an important cause of reduced quality of life and disability
A staged approach, establishing BPC-157 response before adding additional elements, provides clearer information for protocol optimization
NEXT Workout Igor Voitenko specializes in bodyweight exercises with adaptable routines for all fitness levels
While providers manage your prescriptions and check-ins, theres no coaching, nutrition guidance, or behavioral support, so youll be managing your lifestyle changes on your own
Let's create your personalized plan